{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:54:41Z","timestamp":1792122881619,"version":"4.4.0"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The locoregional treatment of high grade serous ovarian cancer (HGSOC) comprises of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Recent evidence form randomized trials, has led to controversy related to the use of HIPEC in addition to interval CRS (iCRS) and the role of secondary CRS (sCRS) in patients with the first platinum\u2010sensitive recurrence from high\u2010grade serous ovarian cancer (HGSOC). This multi\u2010society consensus, coordinated by the Peritoneal Surface Oncology Group International (PSOGI) with inputs from ISSPP, SSO, ESSO, and IGCS, evaluated the role of these interventions using the GRADE ADOLOPMENT methodology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>An international expert panel reviewed evidence for the use of HIPEC in addition to iCRS in stage 3 high grade serous ovarian cancer (HGSOC) and the role of sCRS for patients with platinum\u2010sensitive recurrent HGSOC. A systematic review assessed randomized controlled trials (RCTs) for recurrence\u2010free survival (RFS), overall survival (OS), safety, and quality of life (QoL). Recommendations were formulated using the GRADE Evidence\u2010to\u2010Decision framework.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HIPEC in addition to iCRS was strongly recommended based on the results of the OVHIPEC\u20101 trial, which showed significant benefit in RFS (3.5 months) and OS (12 months) without increasing the grade 3\u20134 morbidity. For the first platinum\u2010sensitive recurrence, a conditional recommendation was made either for sCRS with systemic therapy or systemic therapy alone, reflecting variability in trial outcomes due to heterogeneity in the patient population in the trials and lack of surgical standardization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This consensus highlights the benefits of HIPEC in addition of iCRS and key factors that limit its wide\u2010spread use. It underlines the need for individualized decision\u2010making while selecting patients for sCRS. Future research integrating advanced systemic therapies is essential to refine these recommendations and provide equitable access to these complex locoregional treatments.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.28166","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T08:48:11Z","timestamp":1754642891000},"page":"885-894","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multisocietal Consensus on the Use of Cytoreductive Surgery and HIPEC for the Treatment of Epithelial Ovarian Cancer: A GRADE Approach for Evidence Evaluation and Recommendation"],"prefix":"10.1002","volume":"132","author":[{"given":"Donnal","family":"Brennan","sequence":"first","affiliation":[{"name":"UCD Gynecological Oncology Group, UCD School of Medicine Mater Misericordiae University Hospital Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hawarden","sequence":"additional","affiliation":[{"name":"UCD Gynecological Oncology Group, UCD School of Medicine Mater Misericordiae University Hospital Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-9478","authenticated-orcid":false,"given":"Michela","family":"Cinquini","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-6898","authenticated-orcid":false,"given":"Aditi","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology Shalby Cancer and Research Institute Ahmedabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampige Prasanna","family":"Somashekhar","sequence":"additional","affiliation":[{"name":"Department of Surgical &amp; Gynecological Oncology Aster International Institute of Oncology, Aster Hospital Bangalore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piso","family":"Pompiliu","sequence":"additional","affiliation":[{"name":"Department of General and Visceral Surgery Hospital Barmherzige Br\u00fcder Regensburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1990-2584","authenticated-orcid":false,"given":"Andreas","family":"Brandl","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery University Hospital Heidelberg Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Levine","sequence":"additional","affiliation":[{"name":"Section of Surgical Oncology, Department of Surgery Wake Forest University School of Medicine Winston\u2010Salem North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh H.","family":"Dellinger","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Surgery City of Hope Comprehensive Cancer Center Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoual","family":"Bakrin","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology H\u00f4pita Lyon Sud, Hospices Civils de Lyon Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammartino","family":"Paolo","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology Sapienza University of Rome Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo Dico","family":"Rea","sequence":"additional","affiliation":[{"name":"Department of General and Emergency Surgery S.Camillo\u2010Forlanini Hospital Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Baratti","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology PSM unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-9810","authenticated-orcid":false,"given":"Guaglio","family":"Marcello","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology PSM unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-277X","authenticated-orcid":false,"given":"Shigeki","family":"Kusamura","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology PSM unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deraco","family":"Marcello","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology PSM unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","article-title":"2004 Consensus Statements on the Management of Ovarian Cancer: Final Document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG Occc 2004)","volume":"16","author":"Du Bois A.","year":"2005","journal-title":"Annals of Oncology"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer","volume":"363","author":"Vergote I.","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_9_4_1","first-page":"101","article-title":"Surgical Resection of Tumor Bulk in the Primary Treatment of Ovarian Carcinoma","volume":"42","author":"Griffiths C.","journal-title":"In: National Cancer Institute Monograph"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Wright A. A.","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Van Driel W. J.","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/02656736.2017.1301576","article-title":"Complete Cytoreductive Surgery Plus Hipec for Peritoneal Metastases From Unusual Cancer Sites of Origin: Results From a Worldwide Analysis Issue of the Peritoneal Surface Oncology Group International (PSOGI)","volume":"33","author":"Go\u00e9r\u00e9 D.","year":"2017","journal-title":"International Journal of Hyperthermia"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/IGC.0000000000000664","article-title":"Heated Intraperitoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer","volume":"26","author":"Hotouras A.","year":"2016","journal-title":"International Journal of Gynecological Cancer"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.suronc.2018.05.006","article-title":"HIPEC in Patients With Primary Advanced Ovarian Cancer: Is There a Role? A Systematic Review of Short\u2010 and Long\u2010Term Outcomes","volume":"27","author":"Kireeva G. S.","year":"2018","journal-title":"Surgical Oncology"},{"key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi\u2010Institutional Experience","volume":"27","author":"Yan T. D.","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jviscsurg.2015.11.010","article-title":"Peritoneal Carcinomatosis From Unusual Cancer Origins: Is There a Role for Hyperthermic Intraperitoneal Chemotherapy?","volume":"153","author":"Honor\u00e9 C.","year":"2016","journal-title":"Journal of Visceral Surgery"},{"key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/annonc\/mdy198","article-title":"HIPEC: HOPE or HYPE in the Fight Against Advanced Ovarian Cancer?","volume":"29","author":"Fotopoulou C.","year":"2018","journal-title":"Annals of Oncology"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO\u2013ESMO\u2013ESP Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology and Early, Advanced and Recurrent Disease","volume":"35","author":"Ledermann J. A.","year":"2024","journal-title":"Annals of Oncology"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer","volume":"385","author":"Harter P.","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Platinum\u2010Sensitive Relapsed Ovarian Cancer (SOC\u20101): A Multicentre, Open\u2010Label, Randomised, Phase 3 Trial","volume":"22","author":"Shi T.","year":"2021","journal-title":"Lancet Oncology"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer","volume":"381","author":"Coleman R. L.","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN Guidelines\u00ae Insights: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines","volume":"22","author":"Liu J.","year":"2024","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE Evidence to Decision (ETD) Frameworks for Adoption, Adaptation, and De Novo Development of Trustworthy Recommendations: GRADE\u2010ADOLOPMENT","volume":"81","author":"Sch\u00fcnemann H. J.","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27947"},{"key":"e_1_2_9_20_1","unstructured":"Linea guida AIOM Tumori Peritoneali https:\/\/www.aiom.it\/linee-guida-aiom-2024-tumori-peritoneali-primitivi-e-secondari\/."},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations","volume":"336","author":"Guyatt G. H.","year":"2008","journal-title":"BMJ"},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial","volume":"29","author":"Antonio C. C. P.","year":"2022","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial","volume":"157","author":"Lim M. C.","year":"2022","journal-title":"JAMA Surgery"},{"key":"e_1_2_9_24_1","unstructured":"State of the Society Survey Now Available in SGO Store https:\/\/www.sgo.org\/news\/state-of-the-society-survey-now-available-in-sgo-store\/#:~:text=The%20Society%20of%20Gynecologic%20Oncology plus%20%2412%20shipping%20and%20handling."},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1200\/JCO.19.00594","article-title":"Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial","volume":"37","author":"Koole S. N.","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian Cancer in the World: Epidemiology and Risk Factors","volume":"11","author":"Momenimovahed Z.","year":"2019","journal-title":"International Journal of Women\u2032s Health"},{"key":"e_1_2_9_27_1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO\u2010OVAR) and the Groupe D\u2032Investigateurs Nationaux Pour Les Etudes Des Cancers De L\u2032Ovaire (GINECO)","volume":"115","author":"Du Bois A.","year":"2009","journal-title":"Cancer"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence\u2010Based Proposal for Patient Selection","volume":"19","author":"Tian W.\u2010J.","year":"2012","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"8115","DOI":"10.1245\/s10434-023-13932-3","article-title":"The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer","volume":"30","author":"Bhatt A.","year":"2023","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer (OVHIPEC\u20101): Final Survival Analysis of a Randomised, Controlled, Phase 3 Trial","volume":"24","author":"Aronson S. L.","year":"2023","journal-title":"Lancet Oncology"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2023.03.035","article-title":"Cytoreductive Surgery for Advanced Epithelial Ovarian Cancer in the Poly(ADP\u2010Ribose) Polymerase Inhibitors Era\u2014Is It Time for a New Paradigm Shift? A Systematic Review and Meta\u2010Analysis","volume":"187","author":"Peters I. T. A.","year":"2023","journal-title":"European Journal of Cancer"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ygyno.2020.09.022","article-title":"Current Status of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer in the United States","volume":"159","author":"Charo L. M.","year":"2020","journal-title":"Gynecologic Oncology"},{"key":"e_1_2_9_33_1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ygyno.2020.06.487","article-title":"A Guide to Establishing a Hyperthermic Intraperitoneal Chemotherapy Program in Gynecologic Oncology","volume":"158","author":"Chambers L. M.","year":"2020","journal-title":"Gynecologic Oncology"},{"key":"e_1_2_9_34_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.gore.2022.100945","article-title":"Standardizing HIPEC and Perioperative Care for Patients With Ovarian Cancer in the Netherlands Using a Delphi\u2010Based Consensus","volume":"39","author":"Van Stein R. M.","year":"2022","journal-title":"Gynecologic Oncology Reports"},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ejso.2020.07.041","article-title":"Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS\u00ae) Society Recommendations \u2014 Part I: Preoperative and Intraoperative Management","volume":"46","author":"H\u00fcbner M.","year":"2020","journal-title":"European Journal of Surgical Oncology"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1245\/s10434-024-15042-0","article-title":"Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage Iv and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes","volume":"31","author":"Ghirardi V.","year":"2024","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_9_37_1","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e34","article-title":"Confirmation of the Utility of the CA\u2010125 Elimination Rate (KELIM) as an Indicator of the Chemosensitivity in Advanced\u2010Stage Ovarian Cancer in a \u2018Real\u2010Life Setting","volume":"35","author":"Van Wagensveld L.","year":"2024","journal-title":"Journal of Gynecologic Oncology"},{"key":"e_1_2_9_38_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jogoh.2019.03.018","article-title":"Management of Epithelial Cancer of the Ovary, Fallopian Tube, Primary Peritoneum. Long Text of the Joint French Clinical Practice Guidelines Issued by Francogyn, Cngof, Sfog, Gineco\u2010Arcagy, Endorsed by INCA. (Part 2: Systemic, Intraperitoneal Treatment, Elderly Patients, Fertility Preservation, Follow\u2010Up)","volume":"48","author":"Lavoue V.","year":"2019","journal-title":"Journal of Gynecology Obstetrics and Human Reproduction"},{"key":"e_1_2_9_39_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.5301\/tj.5000623","article-title":"1st Evidence\u2010Based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis From Ovarian Cancer","volume":"103","author":"Cavaliere D.","year":"2017","journal-title":"Tumori Journal"},{"key":"e_1_2_9_40_1","unstructured":"\"NVOG Committee on Gynaecologic Oncology Guidelines \" HIPEC Module for Epithelial Ovarian Cancer \u2013 Advanced Stage (FIGO III). Richtlijnendatabase accessed August 4 2025 https:\/\/richtlijnendatabase.nl\/richtlijn\/ovariumcarcinoom\/behandeling_hoog_stadium_iib_iv\/hipec_hoog_stadium.html."},{"key":"e_1_2_9_41_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1515\/pp-2023-0052","article-title":"Do All Patients That Undergo a \u2018Complete\u2032 Secondary Cytoreductive Surgery for Platinum\u2010Sensitive Recurrent Ovarian Cancer, Benefit From It?","volume":"9","author":"Bhatt A.","year":"2024","journal-title":"Pleura and Peritoneum"},{"key":"e_1_2_9_42_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2023.41.16_suppl.e17601","article-title":"AV. Real\u2010World Outcomes of First\u2010Line Maintenance With Niraparib or Bevacizumab in Advanced Ovarian Cancer","volume":"41","author":"Kudrik F. J.","year":"2023","journal-title":"Journal of Clinical Oncology"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.28166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:41:14Z","timestamp":1759830074000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.28166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/jso.28166"],"URL":"https:\/\/doi.org\/10.1002\/jso.28166","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"2024-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}